CHARLENE JO NARDO: Open Payments
NPI 1477249761 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,282 in 57 payments from 12 companies in 2025. Trend: 2023 $452 · 2024 $963 · 2025 $1,282
Food & beverage: $1,282
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $259 |
| E.R. Squibb & Sons, L.L.C. | 11 | $229 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $183 |
| ABBVIE INC. | 8 | $155 |
| Otsuka America Pharmaceutical, Inc. | 6 | $130 |
| Alkermes, Inc. | 4 | $82 |
| Almatica Pharma LLC | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Indivior Inc. | 1 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
Products named: INGREZZA, COBENFY, CAPLYTA, VRAYLAR, REXULTI, ARISTADA, LOREEV XR, ABILIFY ASIMTUFII.
Industry payments across NV — which companies pay providers there.
